Home > Insider Trading > Filing (0001549595-24-000147)

Filing Details

Accession Number:: 0001549595-24-000147
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-10-30 20:30:17
Reporting Period:: 2024-10-30

Accepted Time:: 2024-10-30 20:30:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1549595	Nurix Therapeutics Inc.	NRIX	Pharmaceutical Preparations (2834)	270838048

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1817160	Gwenn Hansen	C/O Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco CA 94158	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-10-30	3,207	$0.00	48,357	No	4	M	Direct
Common Stock	Acquisiton	2024-10-30	2,000	$0.00	50,357	No	4	M	Direct
Common Stock	Acquisiton	2024-10-30	3,750	$0.00	54,107	No	4	M	Direct
Common Stock	Disposition	2024-10-30	3,437	$24.31	50,670	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-10-30	3,207	$0.00	3,207	$0.00
Common Stock	Restricted Stock Units	Disposition	2024-10-30	2,000	$0.00	2,000	$0.00
Common Stock	Restricted Stock Units	Disposition	2024-10-30	3,750	$0.00	3,750	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,034	No	4	M	Direct
12,000	No	4	M	Direct
37,500	No	4	M	Direct

Footnotes

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
RSUs do not expire; they either vest or are canceled prior to the vest date.
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.